Physician profile
Mukesh Kumar
NPI 1043249634
$7,568.67
in general payments reported to CMS, 2019-2025
31 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $723 · 2021: $991 · 2022: $1,682 · 2023: $1,183 · 2024: $919 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.85 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,561.66 | 2019-2025 | |
| Abiomed | $1,074.90 | 2019-2025 | Impella |
| Medtronic, INC. | $995.00 | 2021-2025 | Resolute Onyx, Symplicity G3, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $796.53 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $522.36 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $294.82 | 2020-2025 | Farxiga |
| Astellas Pharma US INC | $267.66 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $229.87 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $219.19 | 2019-2025 | Camzyos, Eliquis |
| Atricure, INC. | $177.32 | 2023-2025 | Synergy Ablation System |
| Biotronik INC. | $138.51 | 2021 | |
| Kestra Medical Technology Services, INC. | $129.69 | 2024-2025 | Assure Wcd |
| Abbott Laboratories | $123.47 | 2019 | |
| Boston Scientific Corporation | $112.79 | 2021-2022 | |
| Cvrx, INC. | $110.94 | 2024-2025 | Barostim Neo System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $110.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.96 | 2019-2025 | |
| Novo Nordisk INC | $92.20 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $78.35 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.20 | 2021-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $63.10 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $56.01 | 2023 | Inpefa |
| Pfizer INC. | $54.25 | 2022-2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $39.10 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $36.92 | 2022-2025 | Nexletol |
| Insmed, INC. | $30.12 | 2025 | Arikayce |
| Alexion Pharmaceuticals, INC. | $19.36 | 2025 | Ultomiris |
| Kiniksa Pharmaceuticals International, Plc | $18.64 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $16.20 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $12.28 | 2022 | |
| Medtronic Vascular, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.